表紙:バイオシミラーインスリンの世界市場 - 売上:2021年
市場調査レポート
商品コード
1018994

バイオシミラーインスリンの世界市場 - 売上:2021年

Global Biosimilar Insulin Sales Market Report 2021

出版日: | 発行: QYResearch | ページ情報: 英文 124 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.27円
バイオシミラーインスリンの世界市場 - 売上:2021年
出版日: 2021年07月19日
発行: QYResearch
ページ情報: 英文 124 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のバイオシミラーインスリンの市場規模は、2020年の22億9,600万米ドルから、2027年末までに56億5,200万米ドルに達し、2022年~2027年のCAGRで14.19%の成長が予測されています。

当レポートでは、世界のバイオシミラーインスリン市場について調査分析し、セグメント別の市場分析、売上、収益、予測に焦点を当てて、体系的な情報を提供しています。

目次

第1章 バイオシミラーインスリンの市場概要

  • バイオシミラーインスリンの製品範囲
  • バイオシミラーインスリンセグメント:タイプ別
  • バイオシミラーインスリンセグメント:用途別
  • 世界のバイオシミラーインスリン市場の推定と予測

第2章 バイオシミラーインスリンの推定と予測:地域別

  • 世界のバイオシミラーインスリンの市場規模:地域別
  • 世界のバイオシミラーインスリンの遡及的市場シナリオ:地域別
  • 世界のバイオシミラーインスリン市場の推定と予測:地域別
  • 地域別の市場分析:市場ファクト・数値

第3章 バイオシミラーインスリンの競合情勢:企業別

  • 世界のバイオシミラーインスリンの主要企業:売上別
  • 世界のバイオシミラーインスリンの主要企業:収益別
  • 世界のバイオシミラーインスリン:企業タイプ別
  • 世界のバイオシミラーインスリンの平均価格:企業別
  • バイオシミラーインスリンメーカーの製造拠点、提供エリア、製品タイプ
  • メーカーのM&A、拡張計画

第4章 バイオシミラーインスリンの市場規模:タイプ別

  • 世界のバイオシミラーインスリンの過去の市場分析:タイプ別
  • 世界のバイオシミラーインスリン市場の推定と予測:タイプ別

第5章 世界のバイオシミラーインスリンの市場規模:用途別

  • 世界のバイオシミラーインスリンの過去の市場分析:用途別
  • 世界のバイオシミラーインスリン市場の推定と予測:用途別

第6章 米国のバイオシミラーインスリンの市場ファクト・数値

  • 米国のバイオシミラーインスリンの売上:企業別
  • 米国のバイオシミラーインスリンの売上の内訳:タイプ別
  • 米国のバイオシミラーインスリンの売上の内訳:用途別

第7章 欧州のバイオシミラーインスリンの市場ファクト・数値

  • 欧州のバイオシミラーインスリンの売上:企業別
  • 欧州のバイオシミラーインスリンの売上の内訳:タイプ別
  • 欧州のバイオシミラーインスリンの売上の内訳:用途別

第8章 中国のバイオシミラーインスリンの市場ファクト・数値

  • 中国のバイオシミラーインスリンの売上:企業別
  • 中国のバイオシミラーインスリンの売上の内訳:タイプ別
  • 中国のバイオシミラーインスリンの売上の内訳:用途別

第9章 日本のバイオシミラーインスリンの市場ファクト・数値

  • 日本のバイオシミラーインスリンの売上:企業別
  • 日本のバイオシミラーインスリンの売上の内訳:タイプ別
  • 日本のバイオシミラーインスリンの売上の内訳:用途別

第10章 インドのバイオシミラーインスリンの市場ファクト・数値

  • インドのバイオシミラーインスリンの売上:企業別
  • インドのバイオシミラーインスリンの売上の内訳:タイプ別
  • インドのバイオシミラーインスリンの売上の内訳:用途別

第11章 東南アジアのバイオシミラーインスリンの市場ファクト・数値

  • 東南アジアのバイオシミラーインスリンの売上:企業別
  • 東南アジアのバイオシミラーインスリンの売上の内訳:タイプ別
  • 東南アジアのバイオシミラーインスリンの売上の内訳:用途別

第12章 バイオシミラーインスリン事業における企業プロファイルと主要数値

  • Eli Lilly
  • Sanofi
  • Gan&Lee
  • Tonghua Dongbao
  • United Laboratory
  • Geropharm
  • Biocon
  • Wockhardt

第13章 バイオシミラーインスリンの製造コスト分析

  • バイオシミラーインスリンの主要原材料分析
  • 製造コスト構造比
  • バイオシミラーインスリンの製造プロセス分析
  • バイオシミラーインスリンの業界チェーン分析

第14章 マーケティングチャネル・ディストリビューター・顧客

  • マーケティングチャネル
  • バイオシミラーインスリンのディストリビューターリスト
  • バイオシミラーインスリンの顧客

第15章 バイオシミラーインスリンの市場力学

  • バイオシミラーインスリンの業界動向
  • バイオシミラーインスリンの市場促進要因
  • バイオシミラーインスリンの市場課題
  • バイオシミラーインスリンの市場抑制要因

第16章 調査結果・結論

第17章 付録

図表

List of Tables and Figures

  • Table 1. Global Biosimilar Insulin Sales (US$ Million) Growth Rate by Type (2016 & 2021 & 2027)
  • Table 2. Global Biosimilar Insulin Revenue (US$ Million) Comparison by Application (2016 & 2021 & 2027)
  • Table 3. Global Market Biosimilar Insulin Market Size (US$ Million) by Region:2016 VS 2021 &2027
  • Table 4. Global Biosimilar Insulin Sales (K Unit) by Region (2016-2021)
  • Table 5. Global Biosimilar Insulin Sales Market Share by Region (2016-2021)
  • Table 6. Global Biosimilar Insulin Revenue (US$ Million) Market Share by Region (2016-2021)
  • Table 7. Global Biosimilar Insulin Revenue Share by Region (2016-2021)
  • Table 8. Global Biosimilar Insulin Sales (K Unit) Forecast by Region (2022-2027)
  • Table 9. Global Biosimilar Insulin Sales Market Share Forecast by Region (2022-2027)
  • Table 10. Global Biosimilar Insulin Revenue (US$ Million) Forecast by Region (2022-2027)
  • Table 11. Global Biosimilar Insulin Revenue Share Forecast by Region (2022-2027)
  • Table 12. Global Biosimilar Insulin Sales (K Unit) of Key Companies (2016-2021)
  • Table 13. Global Biosimilar Insulin Sales Share by Company (2019-2021)
  • Table 14. Global Biosimilar Insulin Revenue (US$ Million) by Company (2019-2021)
  • Table 15. Global Biosimilar Insulin Revenue Share by Company (2019-2021)
  • Table 16. Global Biosimilar Insulin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Insulin as of 2020)
  • Table 17. Global Market Biosimilar Insulin Average Price (USD/Unit) of Key Company (2019-2021)
  • Table 18. Manufacturers Biosimilar Insulin Manufacturing Sites and Area Served
  • Table 19. Manufacturers Biosimilar Insulin Product Type
  • Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
  • Table 21. Global Biosimilar Insulin Sales (K Unit) by Type (2016-2021)
  • Table 22. Global Biosimilar Insulin Sales Share by Type (2016-2021)
  • Table 23. Global Biosimilar Insulin Revenue (US$ Million) Market Share by Type (2016-2021)
  • Table 24. Global Biosimilar Insulin Revenue Share by Type (2016-2021)
  • Table 25. Global Biosimilar Insulin Price (USD/Unit) by Type (2016-2021)
  • Table 26. Global Biosimilar Insulin Sales (K Unit) by Type (2022-2027)
  • Table 27. Global Biosimilar Insulin Sales Share by Type (2022-2027)
  • Table 28. Global Biosimilar Insulin Revenue (US$ Million) Market Share by Type (2022-2027)
  • Table 29. Global Biosimilar Insulin Revenue Share by Type (2022-2027)
  • Table 30. Global Biosimilar Insulin Price (USD/Unit) by Type (2022-2027)
  • Table 31. Global Biosimilar Insulin Sales (K Unit) by Application (2016-2021)
  • Table 32. Global Biosimilar Insulin Sales Share by Application (2016-2021)
  • Table 33. Global Biosimilar Insulin Revenue (US$ Million) Market Share by Application (2016-2021)
  • Table 34. Global Biosimilar Insulin Revenue Share by Application (2016-2021)
  • Table 35. Global Biosimilar Insulin Price (USD/Unit) by Application (2016-2021)
  • Table 36. Global Biosimilar Insulin Sales (K Unit) by Application (2022-2027)
  • Table 37. Global Biosimilar Insulin Sales Share by Application (2022-2027)
  • Table 38. Global Biosimilar Insulin Revenue (US$ Million) Market Share by Application (2022-2027)
  • Table 39. Global Biosimilar Insulin Revenue Share by Application (2022-2027)
  • Table 40. Global Biosimilar Insulin Price (USD/Unit) by Application (2022-2027)
  • Table 41. USA Biosimilar Insulin Sales by Company (2019-2021) & (K Unit)
  • Table 42. USA Biosimilar Insulin Sales Market Share by Company (2019-2021)
  • Table 43. USA Biosimilar Insulin Revenue by Company (2019-2021) & (US$ Million)
  • Table 44. USA Biosimilar Insulin Revenue Market Share by Company (2019-2021)
  • Table 45. USA Biosimilar Insulin Sales by Type (2016-2021) & (K Unit)
  • Table 46. USA Biosimilar Insulin Sales Market Share by Type (2016-2021)
  • Table 47. USA Biosimilar Insulin Sales by Type (2022-2027) & (K Unit)
  • Table 48. USA Biosimilar Insulin Sales Market Share by Type (2022-2027)
  • Table 49. USA Biosimilar Insulin Sales by Application (2016-2021) & (K Unit)
  • Table 50. USA Biosimilar Insulin Sales Market Share by Application (2016-2021)
  • Table 51. USA Biosimilar Insulin Sales by Application (2022-2027) & (K Unit)
  • Table 52. USA Biosimilar Insulin Sales Market Share by Application (2022-2027)
  • Table 53. Europe Biosimilar Insulin Sales by Company (2019-2021) & (K Unit)
  • Table 54. Europe Biosimilar Insulin Sales Market Share by Company (2019-2021)
  • Table 55. Europe Biosimilar Insulin Revenue by Company (2019-2021) & (US$ Million)
  • Table 56. Europe Biosimilar Insulin Revenue Market Share by Company (2019-2021)
  • Table 57. Europe Biosimilar Insulin Sales by Type (2016-2021) & (K Unit)
  • Table 58. Europe Biosimilar Insulin Sales Market Share by Type (2016-2021)
  • Table 59. Europe Biosimilar Insulin Sales by Type (2022-2027) & (K Unit)
  • Table 60. Europe Biosimilar Insulin Sales Market Share by Type (2022-2027)
  • Table 61. Europe Biosimilar Insulin Sales by Application (2016-2021) & (K Unit)
  • Table 62. Europe Biosimilar Insulin Sales Market Share by Application (2016-2021)
  • Table 63. Europe Biosimilar Insulin Sales by Application (2022-2027) & (K Unit)
  • Table 64. Europe Biosimilar Insulin Sales Market Share by Application (2022-2027)
  • Table 65. China Biosimilar Insulin Sales by Company (2019-2021) & (K Unit)
  • Table 66. China Biosimilar Insulin Sales Market Share by Company (2019-2021)
  • Table 67. China Biosimilar Insulin Revenue by Company (2019-2021) & (US$ Million)
  • Table 68. China Biosimilar Insulin Revenue Market Share by Company (2019-2021)
  • Table 69. China Biosimilar Insulin Sales by Type (2016-2021) & (K Unit)
  • Table 70. China Biosimilar Insulin Sales Market Share by Type (2016-2021)
  • Table 71. China Biosimilar Insulin Sales by Type (2022-2027) & (K Unit)
  • Table 72. China Biosimilar Insulin Sales Market Share by Type (2022-2027)
  • Table 73. China Biosimilar Insulin Sales by Application (2016-2021) & (K Unit)
  • Table 74. China Biosimilar Insulin Sales Market Share by Application (2016-2021)
  • Table 75. China Biosimilar Insulin Sales by Application (2022-2027) & (K Unit)
  • Table 76. China Biosimilar Insulin Sales Market Share by Application (2022-2027)
  • Table 77. Japan Biosimilar Insulin Sales by Company (2019-2021) & (K Unit)
  • Table 78. Japan Biosimilar Insulin Sales Market Share by Company (2019-2021)
  • Table 79. Japan Biosimilar Insulin Revenue by Company (2019-2021) & (US$ Million)
  • Table 80. Japan Biosimilar Insulin Revenue Market Share by Company (2019-2021)
  • Table 81. Japan Biosimilar Insulin Sales by Type (2016-2021) & (K Unit)
  • Table 82. Japan Biosimilar Insulin Sales Market Share by Type (2016-2021)
  • Table 83. Japan Biosimilar Insulin Sales by Type (2022-2027) & (K Unit)
  • Table 84. Japan Biosimilar Insulin Sales Market Share by Type (2022-2027)
  • Table 85. Japan Biosimilar Insulin Sales by Application (2016-2021) & (K Unit)
  • Table 86. Japan Biosimilar Insulin Sales Market Share by Application (2016-2021)
  • Table 87. Japan Biosimilar Insulin Sales by Application (2022-2027) & (K Unit)
  • Table 88. Japan Biosimilar Insulin Sales Market Share by Application (2022-2027)
  • Table 89. India Biosimilar Insulin Sales by Company (2019-2021) & (K Unit)
  • Table 90. India Biosimilar Insulin Sales Market Share by Company (2019-2021)
  • Table 91. India Biosimilar Insulin Revenue by Company (2019-2021) & (US$ Million)
  • Table 92. India Biosimilar Insulin Revenue Market Share by Company (2019-2021)
  • Table 93. India Biosimilar Insulin Sales by Type (2016-2021) & (K Unit)
  • Table 94. India Biosimilar Insulin Sales Market Share by Type (2016-2021)
  • Table 95. India Biosimilar Insulin Sales by Type (2022-2027) & (K Unit)
  • Table 96. India Biosimilar Insulin Sales Market Share by Type (2022-2027)
  • Table 97. India Biosimilar Insulin Sales by Application (2016-2021) & (K Unit)
  • Table 98. India Biosimilar Insulin Sales Market Share by Application (2016-2021)
  • Table 99. India Biosimilar Insulin Sales by Application (2022-2027) & (K Unit)
  • Table 100. India Biosimilar Insulin Sales Market Share by Application (2022-2027)
  • Table 101. Southeast Asia Biosimilar Insulin Sales by Company (2019-2021) & (K Unit)
  • Table 102. Southeast Asia Biosimilar Insulin Sales Market Share by Company (2019-2021)
  • Table 103. Southeast Asia Biosimilar Insulin Revenue by Company (2019-2021) & (US$ Million)
  • Table 104. Southeast Asia Biosimilar Insulin Revenue Market Share by Company (2019-2021)
  • Table 105. Southeast Asia Biosimilar Insulin Sales by Type (2016-2021) & (K Unit)
  • Table 106. Southeast Asia Biosimilar Insulin Sales Market Share by Type (2016-2021)
  • Table 107. Southeast Asia Biosimilar Insulin Sales by Type (2022-2027) & (K Unit)
  • Table 108. Southeast Asia Biosimilar Insulin Sales Market Share by Type (2022-2027)
  • Table 109. Southeast Asia Biosimilar Insulin Sales by Application (2016-2021) & (K Unit)
  • Table 110. Southeast Asia Biosimilar Insulin Sales Market Share by Application (2016-2021)
  • Table 111. Southeast Asia Biosimilar Insulin Sales by Application (2022-2027) & (K Unit)
  • Table 112. Southeast Asia Biosimilar Insulin Sales Market Share by Application (2022-2027)
  • Table 113. Eli Lilly Corporation Information
  • Table 114. Eli Lilly Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2021)
  • Table 115. Eli Lilly Biosimilar Insulin Product
  • Table 116. Eli Lilly Recent Development
  • Table 117. Sanofi Corporation Information
  • Table 118. Sanofi Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2021)
  • Table 119. Sanofi Biosimilar Insulin Product
  • Table 120. Sanofi Recent Development
  • Table 121. Gan&Lee Corporation Information
  • Table 122. Gan&Lee Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2021)
  • Table 123. Gan&Lee Biosimilar Insulin Product
  • Table 124. Gan&Lee Recent Development
  • Table 125. Tonghua Dongbao Corporation Information
  • Table 126. Tonghua Dongbao Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2021)
  • Table 127. Tonghua Dongbao Biosimilar Insulin Product
  • Table 128. Tonghua Dongbao Recent Development
  • Table 129. United Laboratory Corporation Information
  • Table 130. United Laboratory Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2021)
  • Table 131. United Laboratory Biosimilar Insulin Product
  • Table 132. United Laboratory Recent Development
  • Table 133. Geropharm Corporation Information
  • Table 134. Geropharm Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2021)
  • Table 135. Geropharm Biosimilar Insulin Product
  • Table 136. Geropharm Recent Development
  • Table 137. Biocon Corporation Information
  • Table 138. Biocon Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2021)
  • Table 139. Biocon Biosimilar Insulin Product
  • Table 140. Biocon Recent Development
  • Table 141. Wockhardt Corporation Information
  • Table 142. Wockhardt Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2021)
  • Table 143. Wockhardt Biosimilar Insulin Product
  • Table 144. Wockhardt Recent Development
  • Table 145. Market Concentration Rate of Raw Material
  • Table 146. Key Suppliers of Raw Materials
  • Table 147. Manufacturing Cost Structure of Biosimilar Insulin
  • Table 148. Biosimilar Insulin Distributors List
  • Table 149. Biosimilar Insulin Customers List
  • Table 150. Biosimilar Insulin Market Trends
  • Table 151. Biosimilar Insulin Market Drivers
  • Table 152. Biosimilar Insulin Market Challenges
  • Table 153. Biosimilar Insulin Market Restraints
  • Table 154. Research Programs/Design for This Report
  • Table 155. Key Data Information from Secondary Sources
  • Table 156. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Biosimilar Insulin Product Picture
  • Figure 2. Global Biosimilar Insulin Sales Market Share by Type in 2021
  • Figure 3. Global Biosimilar Insulin Sales Market Share by Type in 2027
  • Figure 4. Biosimilar Insulin Glargine Product Picture
  • Figure 5. Biosimilar Insulin Lispro Product Picture
  • Figure 6. Global Biosimilar Insulin Sales Market Share by Application in 2021
  • Figure 7. Global Biosimilar Insulin Sales Market Share by Application in 2027
  • Figure 8. Hospital Examples
  • Figure 9. Retail Pharmacy Examples
  • Figure 10. Global Biosimilar Insulin Sales, (US$ Million), 2016 VS 2021 VS 2027
  • Figure 11. Global Biosimilar Insulin Sales Growth Rate (2016-2027) & (US$ Million)
  • Figure 12. Global Biosimilar Insulin Sales (K Unit) Growth Rate (2016-2027)
  • Figure 13. Global Biosimilar Insulin Price Trends Growth Rate (2016-2027) & (USD/Unit)
  • Figure 14. Global Biosimilar Insulin Revenue Market Share by Region: 2016
  • Figure 15. Global Biosimilar Insulin Revenue Market Share by Region: 2021
  • Figure 16. Global Biosimilar Insulin Revenue Market Share by Region: 2027
  • Figure 17. USA Biosimilar Insulin Revenue (US$ Million) Growth Rate (2016-2027)
  • Figure 18. USA Biosimilar Insulin Sales (K Unit) Growth Rate (2016-2027)
  • Figure 19. Europe Biosimilar Insulin Revenue (US$ Million) Growth Rate (2016-2027)
  • Figure 20. Europe Biosimilar Insulin Sales (K Unit) Growth Rate (2016-2027)
  • Figure 21. China Biosimilar Insulin Revenue (US$ Million) Growth Rate (2016-2027)
  • Figure 22. China Biosimilar Insulin Sales (K Unit) Growth Rate (2016-2027)
  • Figure 23. Japan Biosimilar Insulin Revenue (US$ Million) Growth Rate (2016-2027)
  • Figure 24. Japan Biosimilar Insulin Sales (K Unit) Growth Rate (2016-2027)
  • Figure 25. Southeast Asia Biosimilar Insulin Revenue (US$ Million) Growth Rate (2016-2027)
  • Figure 26. Southeast Asia Biosimilar Insulin Sales (K Unit) Growth Rate (2016-2027)
  • Figure 27. India Biosimilar Insulin Revenue (US$ Million) Growth Rate (2016-2027)
  • Figure 28. India Biosimilar Insulin Sales (K Unit) Growth Rate (2016-2027)
  • Figure 29. Global Largest Biosimilar Insulin Players Market Share by Revenue in Biosimilar Insulin: 2020
  • Figure 30. Global Biosimilar Insulin Revenue Growth Rate by Type in 2020
  • Figure 31. Global Biosimilar Insulin Revenue Growth Rate by Application in 2020
  • Figure 32. USA Biosimilar Insulin Sales Market Share by Type in 2020
  • Figure 33. USA Biosimilar Insulin Sales Market Share by Application in 2020
  • Figure 34. Europe Biosimilar Insulin Sales Market Share by Type in 2020
  • Figure 35. Europe Biosimilar Insulin Sales Market Share by Application in 2020
  • Figure 36. China Biosimilar Insulin Sales Market Share by Type in 2020
  • Figure 37. China Biosimilar Insulin Sales Market Share by Application in 2020
  • Figure 38. Japan Biosimilar Insulin Sales Market Share by Type in 2020
  • Figure 39. Japan Biosimilar Insulin Sales Market Share by Application in 2020
  • Figure 40. India Biosimilar Insulin Sales Market Share by Type in 2020
  • Figure 41. India Biosimilar Insulin Sales Market Share by Application in 2020
  • Figure 42. Southeast Asia Biosimilar Insulin Sales Market Share by Type in 2020
  • Figure 43. Southeast Asia Biosimilar Insulin Sales Market Share by Application in 2020
  • Figure 44. Key Raw Materials Price Trend (USD/g) (Insulin API)
  • Figure 45. Manufacturing Process Analysis of Biosimilar Insulin
  • Figure 46. Biosimilar Insulin Industrial Chain Analysis
  • Figure 47. Channels of Distribution
  • Figure 48. Distributors Profiles
  • Figure 49. Bottom-up and Top-down Approaches for This Report
  • Figure 50. Data Triangulation
  • Figure 51. Key Executives Interviewed 106
目次

Market Analysis and Insights:

The global Biosimilar Insulin market was valued at US$ 2296 million in 2020, will reach US$ 5652 million by the end of 2027, growing at a CAGR of 14.19% during 2022-2027.

Scope and Market Size:

The global Biosimilar Insulin market is segmented by company, region (country), by Type, and By Application. Players, stakeholders, and other participants in the global Biosimilar Insulin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and By Application for the period 2016-2027.

By Company

  • Eli Lilly
  • Sanofi
  • Gan&Lee
  • Tonghua Dongbao
  • United Laboratory
  • Geropharm
  • Biocon
  • Wockhardt

Segment by Type

  • Biosimilar Insulin Glargine
  • Biosimilar Insulin Lispro
  • Other

Segment by Application

  • Hospital
  • Retail Pharmacy
  • Others

By Region

  • USA
  • Europe
  • China
  • Japan
  • Southeast Asia
  • India
  • Other Regions

TABLE OF CONTENTS

1 BIOSIMILAR INSULIN MARKET OVERVIEW

  • 1.1 Biosimilar Insulin Product Scope
  • 1.2 Biosimilar Insulin Segment by Type
    • 1.2.1 Global Biosimilar Insulin Sales by Type (2016 & 2021 & 2027)
    • 1.2.2 Biosimilar Insulin Glargine
    • 1.2.3 Biosimilar Insulin Lispro
  • 1.3 Biosimilar Insulin Segment by Application
    • 1.3.1 Global Biosimilar Insulin Revenue Comparison by Application (2016 & 2021 & 2027)
    • 1.3.2 Hospital
    • 1.3.3 Retail Pharmacy
  • 1.4 Global Biosimilar Insulin Market Estimates and Forecasts (2016-2027)
    • 1.4.1 Global Biosimilar Insulin Market Size in Value Growth Rate (2016-2027)
    • 1.4.2 Global Biosimilar Insulin Market Size in Volume Growth Rate (2016-2027)
    • 1.4.3 Global Biosimilar Insulin Price Trends (2016-2027)

2 BIOSIMILAR INSULIN ESTIMATES AND FORECASTS BY REGION

  • 2.1 Global Biosimilar Insulin Market Size by Region: 2016 VS 2021 VS 2027
  • 2.2 Global Biosimilar Insulin Retrospective Market Scenario by Region (2016-2021)
    • 2.2.1 Global Biosimilar Insulin Sales Market Share by Region (2016-2021)
    • 2.2.2 Global Biosimilar Insulin Revenue Market Share by Region (2016-2021)
  • 2.3 Global Biosimilar Insulin Market Estimates and Forecasts by Region (2022-2027)
    • 2.3.1 Global Biosimilar Insulin Sales Estimates and Forecasts by Region (2022-2027)
    • 2.3.2 Global Biosimilar Insulin Revenue Forecast by Region (2022-2027)
  • 2.4 Geographic Market Analysis: Market Facts & Figures
    • 2.4.1 USA Biosimilar Insulin Estimates and Projections (2016-2027)
    • 2.4.2 Europe Biosimilar Insulin Estimates and Projections (2016-2027)
    • 2.4.3 China Biosimilar Insulin Estimates and Projections (2016-2027)
    • 2.4.4 Japan Biosimilar Insulin Estimates and Projections (2016-2027)
    • 2.4.5 Southeast Asia Biosimilar Insulin Estimates and Projections (2016-2027)
    • 2.4.6 India Biosimilar Insulin Estimates and Projections (2016-2027)

3 BIOSIMILAR INSULIN COMPETITION LANDSCAPE BY PLAYERS

  • 3.1 Global Top Biosimilar Insulin Players by Sales (2019-2021)
  • 3.2 Global Top Biosimilar Insulin Players by Revenue (2019-2021)
  • 3.3 Global Biosimilar Insulin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Insulin as of 2020)
  • 3.4 Global Biosimilar Insulin Average Price by Company (2019-2021)
  • 3.5 Manufacturers Biosimilar Insulin Manufacturing Sites, Area Served, Product Type
  • 3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4 BIOSIMILAR INSULIN MARKET SIZE BY TYPE

  • 4.1 Global Biosimilar Insulin Historic Market Review by Type (2016-2021)
    • 4.1.1 Global Biosimilar Insulin Sales Market Share by Type (2016-2021)
    • 4.1.2 Global Biosimilar Insulin Revenue Market Share by Type (2016-2021)
    • 4.1.3 Global Biosimilar Insulin Price by Type (2016-2021)
  • 4.2 Global Biosimilar Insulin Market Estimates and Forecasts by Type (2022-2027)
    • 4.2.1 Global Biosimilar Insulin Sales Forecast by Type (2022-2027)
    • 4.2.2 Global Biosimilar Insulin Revenue Forecast by Type (2022-2027)
    • 4.2.3 Global Biosimilar Insulin Price Forecast by Type (2022-2027)

5 GLOBAL BIOSIMILAR INSULIN MARKET SIZE BY APPLICATION

  • 5.1 Global Biosimilar Insulin Historic Market Review by Application (2016-2021)
    • 5.1.1 Global Biosimilar Insulin Sales Market Share by Application (2016-2021)
    • 5.1.2 Global Biosimilar Insulin Revenue Market Share by Application (2016-2021)
    • 5.1.3 Global Biosimilar Insulin Price by Application (2016-2021)
  • 5.2 Global Biosimilar Insulin Market Estimates and Forecasts by Application (2022-2027)
    • 5.2.1 Global Biosimilar Insulin Sales Forecast by Application (2022-2027)
    • 5.2.2 Global Biosimilar Insulin Revenue Forecast by Application (2022-2027)
    • 5.2.3 Global Biosimilar Insulin Price Forecast by Application (2022-2027)

6 USA BIOSIMILAR INSULIN MARKET FACTS & FIGURES

  • 6.1 USA Biosimilar Insulin Sales by Company
    • 6.1.1 USA Biosimilar Insulin Sales by Company (2019-2021)
    • 6.1.2 USA Biosimilar Insulin Revenue by Company (2019-2021)
  • 6.2 USA Biosimilar Insulin Sales Breakdown by Type
    • 6.2.1 USA Biosimilar Insulin Sales Breakdown by Type (2016-2021)
    • 6.2.2 USA Biosimilar Insulin Sales Breakdown by Type (2022-2027)
  • 6.3 USA Biosimilar Insulin Sales Breakdown by Application
    • 6.3.1 USA Biosimilar Insulin Sales Breakdown by Application (2016-2021)
    • 6.3.2 USA Biosimilar Insulin Sales Breakdown by Application (2022-2027)

7 EUROPE BIOSIMILAR INSULIN MARKET FACTS & FIGURES

  • 7.1 Europe Biosimilar Insulin Sales by Company
    • 7.1.1 Europe Biosimilar Insulin Sales by Company (2019-2021)
    • 7.1.2 Europe Biosimilar Insulin Revenue by Company (2019-2021)
  • 7.2 Europe Biosimilar Insulin Sales Breakdown by Type
    • 7.2.1 Europe Biosimilar Insulin Sales Breakdown by Type (2016-2021)
    • 7.2.2 Europe Biosimilar Insulin Sales Breakdown by Type (2022-2027)
  • 7.3 Europe Biosimilar Insulin Sales Breakdown by Application
    • 7.3.1 Europe Biosimilar Insulin Sales Breakdown by Application (2016-2021)
    • 7.3.2 Europe Biosimilar Insulin Sales Breakdown by Application (2022-2027)

8 CHINA BIOSIMILAR INSULIN MARKET FACTS & FIGURES

  • 8.1 China Biosimilar Insulin Sales by Company
    • 8.1.1 China Biosimilar Insulin Sales by Company (2019-2021)
    • 8.1.2 China Biosimilar Insulin Revenue by Company (2019-2021)
  • 8.2 China Biosimilar Insulin Sales Breakdown by Type
    • 8.2.1 China Biosimilar Insulin Sales Breakdown by Type (2016-2021)
    • 8.2.2 China Biosimilar Insulin Sales Breakdown by Type (2022-2027)
  • 8.3 China Biosimilar Insulin Sales Breakdown by Application
    • 8.3.1 China Biosimilar Insulin Sales Breakdown by Application (2016-2021)
    • 8.3.2 China Biosimilar Insulin Sales Breakdown by Application (2022-2027)

9 JAPAN BIOSIMILAR INSULIN MARKET FACTS & FIGURES

  • 9.1 Japan Biosimilar Insulin Sales by Company
    • 9.1.1 Japan Biosimilar Insulin Sales by Company (2019-2021)
    • 9.1.2 Japan Biosimilar Insulin Revenue by Company (2019-2021)
  • 9.2 Japan Biosimilar Insulin Sales Breakdown by Type
    • 9.2.1 Japan Biosimilar Insulin Sales Breakdown by Type (2016-2021)
    • 9.2.2 Japan Biosimilar Insulin Sales Breakdown by Type (2022-2027)
  • 9.3 Japan Biosimilar Insulin Sales Breakdown by Application
    • 9.3.1 Japan Biosimilar Insulin Sales Breakdown by Application (2016-2021)
    • 9.3.2 Japan Biosimilar Insulin Sales Breakdown by Application (2022-2027)

10 INDIA BIOSIMILAR INSULIN MARKET FACTS & FIGURES

  • 10.1 India Biosimilar Insulin Sales by Company
    • 10.1.1 India Biosimilar Insulin Sales by Company (2019-2021)
    • 10.1.2 India Biosimilar Insulin Revenue by Company (2019-2021)
  • 10.2 India Biosimilar Insulin Sales Breakdown by Type
    • 10.2.1 India Biosimilar Insulin Sales Breakdown by Type (2016-2021)
    • 10.2.2 India Biosimilar Insulin Sales Breakdown by Type (2022-2027)
  • 10.3 India Biosimilar Insulin Sales Breakdown by Application
    • 10.3.1 India Biosimilar Insulin Sales Breakdown by Application (2016-2021)
    • 10.3.2 India Biosimilar Insulin Sales Breakdown by Application (2022-2027)

11 SOUTHEAST ASIA BIOSIMILAR INSULIN MARKET FACTS & FIGURES

  • 11.1 Southeast Asia Biosimilar Insulin Sales by Company
    • 11.1.1 Southeast Asia Biosimilar Insulin Sales by Company (2019-2021)
    • 11.1.2 Southeast Asia Biosimilar Insulin Revenue by Company (2019-2021)
  • 11.2 Southeast Asia Biosimilar Insulin Sales Breakdown by Type
    • 11.2.1 Southeast Asia Biosimilar Insulin Sales Breakdown by Type (2016-2021)
    • 11.2.2 Southeast Asia Biosimilar Insulin Sales Breakdown by Type (2022-2027)
  • 11.3 Southeast Asia Biosimilar Insulin Sales Breakdown by Application
    • 11.3.1 Southeast Asia Biosimilar Insulin Sales Breakdown by Application (2016-2021)
    • 11.3.2 Southeast Asia Biosimilar Insulin Sales Breakdown by Application (2022-2027)

12 COMPANY PROFILES AND KEY FIGURES IN BIOSIMILAR INSULIN BUSINESS

  • 12.1 Eli Lilly
    • 12.1.1 Eli Lilly Corporation Information
    • 12.1.2 Eli Lilly Biosimilar Insulin Sales, Revenue and Gross Margin (2019-2021)
    • 12.1.3 Eli Lilly Biosimilar Insulin Products Offered
    • 12.1.4 Eli Lilly Recent Development
  • 12.2 Sanofi
    • 12.2.1 Sanofi Corporation Information
    • 12.2.2 Sanofi Biosimilar Insulin Sales, Revenue and Gross Margin (2019-2021)
    • 12.2.3 Sanofi Biosimilar Insulin Products Offered
    • 12.2.4 Sanofi Recent Development
  • 12.3 Gan&Lee
    • 12.3.1 Gan&Lee Corporation Information
    • 12.3.2 Gan&Lee Biosimilar Insulin Sales, Revenue and Gross Margin (2019-2021)
    • 12.3.3 Gan&Lee Biosimilar Insulin Products Offered
    • 12.3.4 Gan&Lee Recent Development
  • 12.4 Tonghua Dongbao
    • 12.4.1 Tonghua Dongbao Corporation Information
    • 12.4.2 Tonghua Dongbao Biosimilar Insulin Sales, Revenue and Gross Margin (2019-2021)
    • 12.4.3 Tonghua Dongbao Biosimilar Insulin Products Offered
    • 12.4.4 Tonghua Dongbao Recent Development
  • 12.5 United Laboratory
    • 12.5.1 United Laboratory Corporation Information
    • 12.5.2 United Laboratory Biosimilar Insulin Sales, Revenue and Gross Margin (2019-2021)
    • 12.5.3 United Laboratory Biosimilar Insulin Products Offered
    • 12.5.4 United Laboratory Recent Development
  • 12.6 Geropharm
    • 12.6.1 Geropharm Corporation Information
    • 12.6.2 Geropharm Biosimilar Insulin Sales, Revenue and Gross Margin (2019-2021)
    • 12.6.3 Geropharm Biosimilar Insulin Products Offered
    • 12.6.4 Geropharm Recent Development
  • 12.7 Biocon
    • 12.7.1 Biocon Corporation Information
    • 12.7.2 Biocon Biosimilar Insulin Sales, Revenue and Gross Margin (2019-2021)
    • 12.7.3 Biocon Biosimilar Insulin Products Offered
    • 12.7.4 Biocon Recent Development
  • 12.8 Wockhardt
    • 12.8.1 Wockhardt Corporation Information
    • 12.8.2 Wockhardt Biosimilar Insulin Sales, Revenue and Gross Margin (2019-2021)
    • 12.8.3 Wockhardt Biosimilar Insulin Products Offered
    • 12.8.4 Wockhardt Recent Development

13 BIOSIMILAR INSULIN MANUFACTURING COST ANALYSIS

  • 13.1 Biosimilar Insulin Key Raw Materials Analysis
    • 13.1.1 Key Raw Materials
    • 13.1.2 Key Raw Materials Price Trend
    • 13.1.3 Key Suppliers of Raw Materials
  • 13.2 Proportion of Manufacturing Cost Structure
  • 13.3 Manufacturing Process Analysis of Biosimilar Insulin
  • 13.4 Biosimilar Insulin Industrial Chain Analysis

14 MARKETING CHANNEL, DISTRIBUTORS AND CUSTOMERS

  • 14.1 Marketing Channel
  • 14.2 Biosimilar Insulin Distributors List
  • 14.3 Biosimilar Insulin Customers

15 BIOSIMILAR INSULIN MARKET DYNAMICS

  • 15.1 Biosimilar Insulin Industry Trends
  • 15.2 Biosimilar Insulin Market Drivers
  • 15.3 Biosimilar Insulin Market Challenges
  • 15.4 Biosimilar Insulin Market Restraints

16 RESEARCH FINDINGS AND CONCLUSION

17 APPENDIX

  • 17.1 Research Methodology
    • 17.1.1 Methodology/Research Approach
    • 17.1.2 Data Source
  • 17.2 Author Details
  • 17.3 Disclaimer